| Literature DB >> 30519637 |
Feng Liu1, Chenyu Wang1, Rongzhen Wang2, Wenge Wang3, Min Li1.
Abstract
OBJECTIVE: To investigate the clinical pathology and prognosis & outcome of Henoch-Schonlein purpura nephritis (HSPN) with renal interstitial lesions.Entities:
Keywords: Clinical manifestations; Pathological manifestations; Renal interstitial lesions
Year: 2018 PMID: 30519637 PMCID: PMC6272053 DOI: 10.1515/med-2018-0088
Source DB: PubMed Journal: Open Med (Wars)
Comparison of general data of each group.
| Item | Group A | Group B | Group C | F/χ2 | p |
|---|---|---|---|---|---|
| Case (n, %) | 25 (16.9) | 105 (70.9) | 18 (12.2) | ||
| Male/female (case) | 16/9 | 61/44 | 9/9 | 0.258 | 0.892 |
| Age | 34.2 ± 13.6 | 33.5 ± 8.9 | 36.4 ± 18.3 | 0.668 | 0.523 |
| Winter and spring onset (n, %) | 15 (60.0) | 64 (60.9) | 11 (61.1) | 3.625 | 0.136 |
| Incentives (n, %) | |||||
| Infection | 3 (12.0) | 10 (9.5) | 2 (11.1) | 5.651 | 0.069 |
| Allergy | 1 (4.0) | 5 (4.8) | 1 (5.6) | 4.625 | 0.093 |
| Extrarenal manifestations (n, %) | |||||
| Abdominal type | 5 (20.0) | 20 (19.0) | 3 (16.7) | 4.256 | 0.103 |
| Articulated | 3 (12.0) | 19 (18.1) | 3 (16.7) | 3.264 | 0.169 |
| Blood index | |||||
| Blood leukocyte (109/L) | 10.9 ± 5.3 | 9.4 ± 4.6 | 9.1 ± 4.2 | 0.625 | 0.586 |
| Hemoglobin (g/L) | 133.5 ± 19.7 | 133.4 ± 18.9 | 131.9 ± 20.6 | 0.369 | 0.751 |
| Platelet (109/L) | 229.6 ± 70.2 | 224.7 ± 70.1 | 226.3 ± 72.6 | 0.450 | 0.614 |
| Urine protein quantification (g/24h) | 2.9 ± 2.6 | 2.8 ± 2.2 | 3.1 ± 2.3 | 0.698 | 0.496 |
| Creatinine (μmol/L) | 66.2 ± 40.1 | 70.1 ± 35.6 | 103.6 ± 63.5ab | 128.652 | 0.001 |
| Urea nitrogen (mmol/L) | 5.6 ± 4.8 | 6.2 ± 5.3 | 10.2 ± 4.6ab | 103.369 | 0.000 |
| eGFRmL·min-1(1.73 m2)-1 | 157.2 ± 50.8 | 114.6 ± 36.5a | 80.3 ± 36.4ab | 136.489 | 0.000 |
| Blood sedimentation (mm/h) | 11.8 ± 8.9 | 13.5 ± 10.2 | 14.7 ± 12.3 | 0.631 | 0.526 |
| C-reactive protein (mg/L) | 6.5 ± 9.6 | 7.7 ± 10.3 | 8.1 ± 9.5 | 0.463 | 0.601 |
| Serum IgA (mg/L) | 24.6 ± 9.2 | 30.2 ± 10.4 | 31.4 ± 24.9 | 0.708 | 0.520 |
| Urinary β2-microglobulin (μg·L-1) | 159.2 (59.2, 405.3) | 90.3 (53.9, 174.3) | 76.9 (27.4, 277.6) | 0.694 | 0.503 |
| Urinary NAG (U·L-1) | 29.6 (8.3, 32.9) | 11.6 (6.5, 21.3) | 12.9 (7.6, 64.9) | 0.584 | 0.587 |
Compared with group A, ap < 0.05; compared with group B, bp < 0.05. NAG, N-acetyl β-D-glycosaminidase.
Comparison of clinical manifestations and pathological types in each group.
| Item | Group A | Group B | Group C | F/χ2 | p |
|---|---|---|---|---|---|
| Clinical manifestations | 0.421 | 0.796 | |||
| I | 5 | 25 | 4 | ||
| II | 12 | 53 | 8 | ||
| III | 2 | 4 | 1 | ||
| IV | 4 | 20 | 3 | ||
| V | 1 | 1 | 0 | ||
| VI | 1 | 2 | 2 | ||
| Pathological type | 0.436 | 0.803 | |||
| I | 2 | 4 | 1 | ||
| II | 4 | 25 | 2 | ||
| III | 15 | 72 | 13 | ||
| IV | 3 | 3 | 1 | ||
| V | 0 | 0 | 0 | ||
| VI | 1 | 1 | 1 | ||
| Glomerular sclerosis ratio (%) | 6.1 ± 9.7 | 5.4 ± 7.8 | 8.9 ± 11.9ab | 110.692 | 0.002 |
| Crescent moon Ratio (%) | 7.2 ± 11.3 | 9.5 ± 12.8 | 10.8 ± 13.1 | 0.265 | 0.436 |
| Immunophenotyping | 0.436 | 0.821 | |||
| IgA deposition alone | 3 | 14 | 1 | ||
| IgA + IgM deposition | 8 | 34 | 4 | ||
| IgA + IgG deposition | 2 | 13 | 2 | ||
| IgA + IgG + IgM deposition | 12 | 44 | 11 |
Compared with group A, ap < 0.05; compared with group B, bp < 0.05.
Figure 1Corresponding analysis of clinical type and pathological type. According to pathological type (I = 1, II = 2, IIIa = 3, IIIb = 4, IV = 5, VI = 6) and clinical classification (I = 1, II = 2, III = 3, IV = 4, V = 5, VI = 6). After the data is assigned, the corresponding analysis is used, χ2 = 0.252, p = 0.002.
Relationship between renal tubular injury and red blood cell count in urine sediment.
| Item | Urinary sediment red blood cell count | χ2 | p |
|---|---|---|---|
| Group A (n = 25) | 48.60 (6.00-265.97) | ||
| Group B (n = 105) | 72.65 (18.15-369.67)a | 0.028 | 0.003 |
| Group C (n = 18) | 266.00 (42.25-1,150.48)ab |
Compared with group A, ap<0.05; compared with group B, bp < 0.05.
Prognosis of the three groups after follow-up in 5 years after treatment.
| Outcome | Group A | Group B | Group C | χ2 | p |
|---|---|---|---|---|---|
| (n = 25) | (n = 105) | (n = 18) | |||
| Complete relief | 12 (48.0) | 36 (34.3)a | 4 (22.2)ab | ||
| Partial relief | 11 (44.0) | 35 (33.3)a | 5 (27.8)ab | 18.561 | 0.000 |
| Not relieved | 2 (8.0) | 33 (31.4)a | 6 (33.3)a | ||
| End-stage renal disease | 0 | 1 (1.0)a | 3 (16.7)ab |
Compared with group A, ap < 0.05; compared with group B, bp < 0.05.